AVE-Avecho Biotechnology Limited today closed up 25% to finish at 0.5c on $280k stock traded. There was no news out today but on Tuesday they announced recruitment had started for its Phase III Clinical Trial testing its oral cannabidiol TPM-enhanced soft-gel capsule for insomnia.
The Trial is the largest insomnia study of its kind testing cannabidiol, seeking to recruit 519 patients across sites located across Australia.
The trial will compare nightly doses of its proprietary oral cannabidiol TPM-enhanced soft-gel capsules at doses of 75mg and 150mg cannabidiol with placebo over an 8-week dosing period.
In Australia, as many as 60% of the population have at least some symptoms of insomnia with a total cost to the Australian economy estimated to be $19.1 billion, the global insomnia market is estimated at more than $4 billion.
Last night, Avecho was featured onChannel 9 news in the 4pm and 6pm national bulletins, you can find it on the link below:
